

Announcement September 16th, 2008**Results as of June 30th, 2008 (6 months)****Vemedia Pharma shows strong growth, both internal and through acquisitions**

Key figures June 2008

Pro-forma consolidated results (in '000 EUR, non-audited, non-IFRS)	6 months		Evolution 2008
	30-jun-07	30-jun-08	
Net Sales	20.890	26.048	24,7%
EBITDA	3.235	5.438	68,1%

Comments

Consolidated turnover increased by 25% compared to the same period last year. This growth is partly due to the takeover of Methapharma NV in Belgium (in July 2007) and the acquisition of the Valdispert brand from Solvay Pharmaceuticals as from May 15th of this year.

In Belgium, ABC Chemicals that sells raw materials to pharmacists increased its sales by 22% compared to the first year-half of 2007. The operational integration of Methapharma, active in the promotion of food supplements to doctors and pharmacists, is a fact and through this division several items from the Vemedia product range are introduced in Belgium. An example is the launch of Dagravit multi-vitamin products in a campaign around Olympic silver medal winner Kim Gevaert.

Turnover in the Netherlands also grew by 6%.

The Valdispert acquisition in May 2008 already contributed, to a limited extent, to the growth and even had a positive impact on the EBITDA.

With these figures, Vemedia continues its growth path.

Business Outlook

Thanks to the acquisition of Valdispert, a product against stress- and sleeping disorder based on valerian plant extract, Vemedia has become an European player on the 'over-the-counter' (OTC) market. Valdispert is an important product in Germany, Italy, Spain and Portugal and exported to Brazil and South-Africa.



This European presence offers an excellent platform to the company for further growth. The focus is on Italy, Portugal and Spain. In Spain Vemedia also took over a team of sales reps from Solvay Pharmaceuticals.

About Vemedia Pharma

Vemedia Pharma is a leading and innovative player in OTC, self medication and raw materials for the preparation of medicines by pharmacists. The company is active in Europe and outside through export.

For further information, please contact:

Yvan Vindevogel	CEO	+32 (0) 475 45 33 20	yvanvindevogel@pandora.be
Rob Drenth	COO	+31 (0) 20 51 98 203	rob.drenth@vemedia.nl
Jean-Yves De Vel	CFO	+32 (0) 476 49 50 25	jean-yves.de.vel@vemedia.be

www.vemediapharma.com

Kortrijk, September 16th, 2008